Influenza vaccination and the ‘diversity paradox’

Human Vaccines and Immunotherapeutics

Volumn 14, Issue 12, 2018, Pages 3005-3009

  Thompson, Craig P ^a   Obolski, Uri ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antigenic drift; antigenic evolution; antigenic thrift; Influenza; seasonal vaccine; universal vaccine; vaccination; vaccine

Indexed keywords

EPITOPE; FLUOXETINE; GAMMA INTERFERON; HEMAGGLUTININ; INFLUENZA VACCINE; M 001; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SYNTHETIC PEPTIDE; VIRAL PROTEIN; VIRUS VACCINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGENICITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXICITY; DRUG EFFICACY; EPIDEMIC; GENE MUTATION; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; MORBIDITY; MORTALITY; MUTATION; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN STRUCTURE; RISK FACTOR; T LYMPHOCYTE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 85053764870     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2018.1504596     Document Type: Note

References (50)

1. Miller MA, Viboud C, Balinska M, Simonsen L., 2009. The signature features of influenza pandemics — implications for policy. N Engl J Med. 360:2595–2598. https://www.nejm.org/doi/full/10.1056/NEJMp0903906
2. Kilbourne ED. 2006. Influenza pandemics of the 20th century. Emerg Infect Dis. 12:9–14. doi:10.3201/eid1201.051254.
3. WHO. Influenza factsheet. 2018. Geneva, Switzerland: World Health Organisation
4. WHO. Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. WHO Weeky Epidemiol Rec. 2015;90:545–560.
5. Paules C, Subbarao K. 2017. Influenza. Lancet. 390:697–708. doi:10.1016/S0140-6736(17)30129-0.
6. Rambaut, A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature. 2008;453:615–619. doi:10.1038/nature06945.
7. Francis T, Magill TP. The antibody response of human subjects vaccinated with the virus of human influenza. J Exp Med. 65;1937:251–259.
8. WHO. WHO report on global surveillance of epidemic-prone infectious diseases. Who (2000).
9. Schotsaert M, García-Sastre A. 2017. Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol. 23:102–106. doi:10.1016/j.coviro.2017.04.005.
10. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine. 34;2016:4092–4102.
11. Plant EP, Fredell LJ, Hatcher BA, Li X, Chiang MJ, Kosikova M, Xie H, Zoueva O, Cost AA, Ye Z, Cooper MJ. Different repeat annual influenza vaccinations improve the antibody response to drifted influenza strains. Sci Rep. 2017;7. doi:10.1038/s41598-017-05579-4.
12. Snape MD, Pollard AJ. 2013. The beginning of the end for serogroup B meningococcus? Lancet. 381:785–787. doi:10.1016/S0140-6736(12)62194-1.
13. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349. doi:10.1136/bmj.g5725.
14. Harper DM, DeMars LR. 2017. HPV vaccines–A review of the first decade. Gynecol Oncol. 146:196–204. doi:10.1016/j.ygyno.2017.04.004.
15. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis. 2016;213:1546–1556. doi:10.1093/infdis/jiv577.
16. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis. 2016;63:1564–1573. doi:10.1093/cid/ciw635.
17. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, et al. Influenza vaccine effectiveness in the United States during the 2015–2016 season. N Engl J Med. 2017;377:534–543. doi:10.1056/NEJMoa1700153.
18. Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Interim estimates of 2016–17 seasonal influenza vaccine effectiveness — United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017;66:167–171. doi:10.15585/mmwr.mm6606a3.
19. Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, et al. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness — United States, February 2018. Am J Transpl. 2018;18:1020–1025. doi:10.1111/ajt.14730.
20. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci. 2014;111:15798–15803. doi:10.1073/pnas.1409171111.
21. Xie H, Wan XF, Ye Z, Plant EP, Zhao Y, Xu Y, Li X, Finch C, Zhao N, Kawano T, et al. H3N2 mismatch of 2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci Rep. 2015;5. doi:10.1038/srep15279.
22. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE, et al.Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci. 2017;114:201712377. doi:10.1073/pnas.1712377114.
23. WHO. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec. 2016;91:121–132.
24. Cobey S, Hensley SE. 2017. Immune history and influenza virus susceptibility. Curr Opin Virol. 22:105–111. doi:10.1016/j.coviro.2016.12.004.
25. Huang KY, Rijal P, Schimanski L, Powell TJ, Lin TY, McCauley JW, Daniels RS, Townsend AR. Focused antibody response to influenza linked to antigenic drift. J Clin Invest. 2015;125:2631–2645. doi:10.1172/JCI80323.
26. Liu M, Zhao X, Hua S, Du X, Peng Y, Li X, Lan Y, Wang D, Wu A, Shu Y, et al. Antigenic patterns and evolution of the human influenza A (H1N1) virus. Sci Rep. 2015;5:14171. doi:10.1038/srep14171.
27. Carter DM, Bloom CE, Nascimento EJ, Marques ET, Craigo JK, Cherry JL, Lipman DJ, Ross TM. Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol. 2013;87:1400–1410. doi:10.1128/JVI.02257-12.
28. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, Wrammert J, Esposito S, et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med. 2013;210:1493–1500. doi:10.1084/jem.20130166.
29. Francis T. On the doctrine of original antigenic sin ON THE DOCTRINE OF ORIGINAL ANTIGENIC SIN *. Source Proc Am Philos Soc. 104;1960:572–578.
30. Gagnon A, Acosta E, Hallman S, Bourbeau R, Dillon LY, Ouellette N, Earn DD, Herring DA, Inwood K, Madrenas J, et al. Pandemic paradox: early life H2N2 pandemic influenza infection enhanced susceptibility to death during the 2009 H1N1 pandemic. MBio. 2018;9. doi:10.1128/mBio.02091-17.
31. Gostic KM, Ambrose M, Worobey M, Lloyd-Smith JO. 2016. Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science. 354:722–726. doi:10.1126/science.aag1322.
32. Recker M, Pybus OG, Nee S, Gupta S. 2007. The generation of influenza outbreaks by a network of host immune responses against a limited set of antigenic types. Proc Natl Acad Sci. 104:7711–7716. doi:10.1073/pnas.0702154104.
33. Koelle K, Cobey S, Grenfell B, Pascual M. 2006. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science. 314:1898–1903. doi:10.1126/science.1132745.
34. Ferguson NM, Galvani AP, Bush RM. 2003. Ecological and immunological determinants of influenza evolution. Nature. 422:428–433. doi:10.1038/nature01509.
35. Zinder D, Bedford T, Gupta S, Pascual M. The roles of competition and mutation in shaping antigenic and genetic diversity in influenza. PLoS Pathog. 2013;9. doi:10.1371/journal.ppat.1003104.
36. Gupta S, Ferguson N, Anderson R. 1998. Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents. Science. 280:912–915. doi:10.1126/science.280.5365.912.
37. Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O’Connor D, Bowden TA, et al. A naturally protective epitope of limited variability as an influenza vaccine target. Nat Commun. 2018. doi:10.1038/s41467-018-06228-8. [Epub ahead of print]
38. Nogales A, Piepenbrink MS, Wang J, Ortega S, Basu M, Fucile CF, Treanor JJ, Rosenberg AF, Zand MS, Keefer MC, et al. A highly potent and broadly neutralizing H1 influenza-specific human monoclonal antibody. Sci Rep. 2018;8. doi:10.1038/s41598-018-22307-8.
39. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol. 2011;85:10905–10908. doi:10.1128/JVI.00700-11.
40. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci. 2011;108:14216–14221. doi:10.1073/pnas.1111497108.
41. Doud MB, Lee JM, Bloom JD. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat Commun. 2018;9. doi:10.1038/s41467-018-03665-3.
42. Doud MB, Hensley SE, Bloom JD. Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog. 2017;13. doi:10.1371/journal.ppat.1006271.
43. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 87:6542–6550. doi:10.1128/JVI.00641-13.
44. Byrd-Leotis L, Galloway SE, Agbogu E, Steinhauer DA. 2015. Influenza hemagglutinin (HA) stem region mutations that stabilize or destabilize the structure of multiple HA subtypes. J Virol. 89:4504–4516. doi:10.1128/JVI.00057-15.
45. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349:1301–1306. doi:10.1126/science.aac7263.
46. Dilillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo. Nat Med. 20:143–151. doi:10.1038/nm.3443.
47. Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, et al. Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus a in healthy adults [EBioMedicine 29 (2018) 146–154] (S2352396418300653) (10.1016/j.ebiom.2018.02.011)). EBioMedicine. 2018;31:321. doi:10.1016/j.ebiom.2018.05.001.
48. Powell TJ, Silk JD, Sharps J, Fodor E, Townsend ARM. 2012. Pseudotyped influenza a virus as a vaccine for the induction of heterotypic immunity. J Virol. 86:13397–13406. doi:10.1128/JVI.01820-12.
49. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One. 2012;7. doi:10.1371/journal.pone.0048322.
50. van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, Frijlink HW, Hak E. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine. Med (United States). 2017;96:e6339.